A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck †
Titel:
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck †
Auteur:
Abdul Razak, A.R. Soulières, D. Laurie, S.A. Hotte, S.J. Singh, S. Winquist, E. Chia, S. Le Tourneau, C. Nguyen-Tan, P.- F. Chen, E.X. Chan, K.K. Wang, T. Giri, N. Mormont, C. Quinn, S. Siu, L.L.